Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates

Pharmacol Rev. 2024 Apr 15:PHARMREV-AR-2023-001084. doi: 10.1124/pharmrev.123.001084. Online ahead of print.ABSTRACTIn the era of precision medicine, Antibody-Drug Conjugates (ADCs) have emerged as a cutting-edge therapeutic strategy. These innovative compounds combine the precision of monoclonal antibodies with the potent cell-killing or immune-modulating abilities of attached drug payloads. This unique strategy not only reduces off-target toxicity but also enhances the therapeutic effectiveness of drugs. Beyond their well-established role in oncology, ADCs are now showing promising potential in addressing the unmet needs in the therapeutics of rheumatic diseases. Rheumatic diseases, a diverse group of chronic autoimmune diseases with varying etiologies, clinical presentations, and prognoses, often demand prolonged pharmacological interventions, creating a pressing need for novel, efficient and low-risk treatment options. ADCs, with their ability to precisely target the immune components, have emerged as a novel therapeutic strategy in this context. This review will provide an overview of the core components and mechanisms behind ADCs, a summary of the latest clinical trials of ADCs for the treatment if rheumatic diseases, as well as a discussion on the challenges and future prospects faced by the development of next-generation ADCs. Significance Statement There is a lack of efficient and low-risk targeted therapeutics for rheumatic diseases. Antibody-drug conjugates, a clas...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Source Type: research